Non-motor features of Parkinson disease

AHV Schapira, KR Chaudhuri, P Jenner - Nature Reviews …, 2017 - nature.com
Many of the motor symptoms of Parkinson disease (PD) can be preceded, sometimes for
several years, by non-motor symptoms that include hyposmia, sleep disorders, depression …

Therapeutic potential of autophagy-enhancing agents in Parkinson's disease

TE Moors, JJM Hoozemans, A Ingrassia… - Molecular …, 2017 - Springer
Converging evidence from genetic, pathological and experimental studies have increasingly
suggested an important role for autophagy impairment in Parkinson's Disease (PD). Genetic …

microRNAs in Parkinson's disease: from pathogenesis to novel diagnostic and therapeutic approaches

L Leggio, S Vivarelli, F L'Episcopo, C Tirolo… - International journal of …, 2017 - mdpi.com
Parkinson's disease (PD) is the most prevalent central nervous system (CNS) movement
disorder and the second most common neurodegenerative disease overall. PD is …

Parkinson's disease, aging and adult neurogenesis: Wnt/β‐catenin signalling as the key to unlock the mystery of endogenous brain repair

B Marchetti, C Tirolo, F L'Episcopo, S Caniglia… - Aging cell, 2020 - Wiley Online Library
A common hallmark of age‐dependent neurodegenerative diseases is an impairment of
adult neurogenesis. Wingless‐type mouse mammary tumor virus integration site (Wnt)/β …

Glucocerebrosidase and Parkinson disease: recent advances

AHV Schapira - Molecular and cellular neuroscience, 2015 - Elsevier
Mutations of the glucocerebrosidase (GBA) gene are the most important risk factor yet
discovered for Parkinson disease (PD). Homozygous GBA mutations result in Gaucher …

Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration

J Stockwell, E Jakova, FS Cayabyab - Molecules, 2017 - mdpi.com
The inhibitory adenosine A1 receptor (A1R) and excitatory A2A receptor (A2AR) are
predominantly expressed in the brain. Whereas the A2AR has been implicated in normal …

The ongoing pursuit of neuroprotective therapies in Parkinson disease

D Athauda, T Foltynie - Nature Reviews Neurology, 2015 - nature.com
Many agents developed for neuroprotective treatment of Parkinson disease (PD) have
shown great promise in the laboratory, but none have translated to positive results in …

Glucocerebrosidase mutations in Parkinson disease

G O'Regan, RM deSouza, R Balestrino… - Journal of …, 2017 - content.iospress.com
Following the discovery of a higher than expected incidence of Parkinson Disease (PD) in
Gaucher disease, a lysosomal storage disorder, mutations in the glucocerebrocidase (GBA) …

Vitamin D treatment attenuates neuroinflammation and dopaminergic neurodegeneration in an animal model of Parkinson's disease, shifting M1 to M2 microglia …

R Calvello, A Cianciulli, G Nicolardi… - Journal of Neuroimmune …, 2017 - Springer
Microglia-mediated neuroinflammation has been described as a common hallmark of
Parkinson's disease (PD) and is believed to further exacerbate the progressive …

Wnt/β-catenin signaling pathway governs a full program for dopaminergic neuron survival, neurorescue and regeneration in the MPTP mouse model of Parkinson's …

B Marchetti - International journal of molecular sciences, 2018 - mdpi.com
Wingless-type mouse mammary tumor virus (MMTV) integration site (Wnt) signaling is one of
the most critical pathways in developing and adult tissues. In the brain, Wnt signaling …